What is the appropriate evaluation and management for intense fluorodeoxyglucose uptake in the ascending and descending aorta on PET‑CT with a new pleural effusion following percutaneous coronary intervention?

Evaluation and Management of FDG Uptake in Aorta with Pleural Effusion Post-PCI

The intense FDG uptake in the ascending and descending aorta most likely represents active atherosclerotic inflammation rather than large vessel vasculitis, and the pleural effusion requires diagnostic thoracentesis with cytology and culture to exclude malignancy, infection, or post-procedural complications.

Initial Diagnostic Approach

Aortic FDG Uptake Interpretation

FDG uptake in the aortic wall following PCI is commonly observed and typically indicates metabolically active atherosclerotic disease rather than vasculitis. 1 The pattern you describe—diffuse uptake in ascending and descending aorta—is characteristic of atherosclerotic inflammation, particularly in patients with recent coronary intervention. 2

Key distinguishing features:

• Atherosclerotic uptake is typically diffuse, intermediate intensity, and most prominent in the descending aorta 1
• Vasculitis (GCA/TAK) would be unusual in this clinical context and typically presents with constitutional symptoms and elevated inflammatory markers 3
• Post-PCI patients demonstrate increased arterial FDG uptake that correlates with cardiovascular risk and may predict future cardiovascular events 4

Pleural Effusion Evaluation

The new pleural effusion requires immediate diagnostic evaluation with thoracic ultrasound followed by thoracentesis. 5

Perform thoracic ultrasound first to:

• Confirm effusion size and safety for aspiration 5
• Assess for pleural nodularity or thickening suggesting malignancy 5
• Guide safe diagnostic aspiration 5

FDG uptake in pleural disease has high diagnostic accuracy (sensitivity 96.8%, specificity 88.5%) for distinguishing malignant from benign effusions. 6 However, false positives occur with parapneumonic effusions and tuberculosis. 6

Differential Diagnosis Priority

For the Pleural Effusion:

1. Malignant effusion - FDG-avid pleural disease has 93.8% positive predictive value for malignancy 6
2. Post-procedural complication - hemothorax, chylothorax, or iatrogenic injury
3. Parapneumonic/infectious - can show intense FDG uptake 6
4. Heart failure exacerbation - though typically bilateral
5. Pulmonary embolism - consider given recent PCI 5

For the Aortic Uptake:

1. Active atherosclerosis - most likely given PCI context 2, 1
2. Large vessel vasculitis - unlikely without systemic symptoms 3
3. Aortic infection/endovascular infection - critical to exclude given recent intervention 7

Immediate Management Steps

Obtain diagnostic thoracentesis with the following studies:

• Cell count with differential
• Protein, LDH, glucose (Light's criteria)
• Cytology (send adequate volume, typically 50-100mL) 5
• Bacterial and mycobacterial cultures
• Consider pH if infection suspected 5

Review for post-PCI complications:

• Check for signs of device infection (fever, bacteremia, new murmur) 7
• Assess for hemodynamic instability
• Review procedural details for potential vascular injury

Correlate with clinical presentation:

• Fever and elevated inflammatory markers suggest infection (pleural or vascular) 3, 7
• Chest pain and dyspnea severity
• Timing relative to PCI procedure

Risk Stratification

The extensive arterial FDG uptake indicates high cardiovascular risk. Patients with significant arterial FDG uptake have substantially higher rates of cardiovascular events (30% vs 1.8% for recent events). 4 This finding warrants:

• Aggressive cardiovascular risk factor modification
• High-intensity statin therapy (atorvastatin 20mg or equivalent reduces aortic FDG uptake) 2
• Close cardiovascular follow-up

When to Consider Vasculitis

Only pursue large vessel vasculitis workup if: 3

• Constitutional symptoms present (fever, weight loss, night sweats)
• Persistently elevated ESR/CRP without alternative explanation
• New ischemic events in non-atherosclerotic distribution
• Imaging shows vessel wall thickening on CT/MRI beyond atherosclerotic changes

Do not routinely use FDG-PET for vasculitis monitoring in remission as persistent uptake has unclear clinical significance. 3

Critical Pitfalls to Avoid

• Do not assume benign atherosclerotic uptake without excluding infection, especially post-procedure 7
• Do not delay pleural fluid sampling if effusion is accessible—early diagnosis changes management 5
• Moderate FDG uptake in pleura can occur with benign disease (parapneumonic, tuberculous, uremic pleurisy) 6
• Do not perform blind thoracentesis—always use ultrasound guidance 5
• If thoracentesis is unsafe or non-diagnostic, proceed to contrast-enhanced CT chest/abdomen/pelvis 5

Follow-up Imaging Strategy

If pleural effusion is malignant: Consider indwelling pleural catheter versus talc pleurodesis based on patient preference and prognosis 8

For aortic surveillance: MRA, CTA, or ultrasound may be used for long-term monitoring of structural damage at sites of preceding inflammation, though frequency should be individualized 3

Repeat imaging is not routinely indicated for atherosclerotic aortic uptake unless clinical deterioration occurs or vasculitis becomes suspected. 3